Collegium Pharmaceutical (COLL) to Release Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $2.20 per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $45.29 on Thursday. The business’s 50-day moving average price is $47.10 and its 200-day moving average price is $41.52. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $50.79. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of 28.13 and a beta of 0.64. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71.

Wall Street Analyst Weigh In

COLL has been the subject of a number of research reports. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a research note on Tuesday, February 10th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target (up previously from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Finally, Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $53.40.

Insiders Place Their Bets

In related news, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the transaction, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. The trade was a 14.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $47.03, for a total transaction of $171,659.50. Following the sale, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. This trade represents a 6.49% decrease in their position. The SEC filing for this sale provides additional information. 2.51% of the stock is owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in COLL. Group One Trading LLC acquired a new position in Collegium Pharmaceutical during the 4th quarter valued at about $28,000. Kemnay Advisory Services Inc. bought a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $61,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 744.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after purchasing an additional 2,190 shares in the last quarter. NewEdge Advisors LLC grew its holdings in Collegium Pharmaceutical by 304.6% during the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 2,294 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Collegium Pharmaceutical by 444.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,551 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 2,899 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.